TY - JOUR
T1 - Neurocardiac protection with milrinone for restoring acute cerebral hypoperfusion and delayed ischemic injury after experimental subarachnoid hemorrhage
AU - Mutoh, Tomoko
AU - Mutoh, Tatsushi
AU - Sasaki, Kazumasu
AU - Nakamura, Kazuhiro
AU - Tatewaki, Yasuko
AU - Ishikawa, Tatsuya
AU - Taki, Yasuyuki
N1 - Funding Information:
This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (15K10966), Life Science Foundation of Japan, and Cooperative Research Project Program of Joint Usage/Research Center at the IDAC, Tohoku University.
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/2/15
Y1 - 2017/2/15
N2 - Background and purpose Acute cerebral hypoperfusion following subarachnoid hemorrhage (SAH) is highly related to the pathogenesis of delayed cerebral ischemia (DCI), but the therapeutic option is poorly available. This study aimed to clarify the effect of milrinone (MIL) on cerebral blood flow (CBF) and related outcomes after experimental SAH. Methods Twenty-seven male C57BL/6 mice were assigned to either sham surgery (SAH-sham; n = 6), SAH induced by endovascular perforation (control; n = 10), or SAH followed by cardiac support with intravenous MIL (n = 11) performed 1.5-h after SAH induction. CBF, neurobehavioral function, occurrence of DCI were assessed by MR-continuous arterial spin labeling, daily neurological score testing, and diffusion- and T2-weighted MR images on days 1 and 3, respectively. Results Initial global CBF depression was notable in mice of control and MIL groups as compared to the SAH-sham group (P < 0.05). MIL raised CBF in a dose-dependent manner (P < 0.001), resulted in lower incidence of DCI (P = 0.008) and better recovery from neurobehavioral decline than control (P < 0.001). The CBF values on day 1 predicted DCI with a cut-off of 42.5 ml/100 g/min (82% specificity and 83% sensitivity), which was greater in mice treated with MIL than those of control (51.7 versus 37.6 ml/100 g/min; P < 0.001). Conclusion MIL improves post-SAH acute hypoperfusion that can lead to the prevention of DCI and functional worsening, acting as a neurocardiac protective agent against EBI.
AB - Background and purpose Acute cerebral hypoperfusion following subarachnoid hemorrhage (SAH) is highly related to the pathogenesis of delayed cerebral ischemia (DCI), but the therapeutic option is poorly available. This study aimed to clarify the effect of milrinone (MIL) on cerebral blood flow (CBF) and related outcomes after experimental SAH. Methods Twenty-seven male C57BL/6 mice were assigned to either sham surgery (SAH-sham; n = 6), SAH induced by endovascular perforation (control; n = 10), or SAH followed by cardiac support with intravenous MIL (n = 11) performed 1.5-h after SAH induction. CBF, neurobehavioral function, occurrence of DCI were assessed by MR-continuous arterial spin labeling, daily neurological score testing, and diffusion- and T2-weighted MR images on days 1 and 3, respectively. Results Initial global CBF depression was notable in mice of control and MIL groups as compared to the SAH-sham group (P < 0.05). MIL raised CBF in a dose-dependent manner (P < 0.001), resulted in lower incidence of DCI (P = 0.008) and better recovery from neurobehavioral decline than control (P < 0.001). The CBF values on day 1 predicted DCI with a cut-off of 42.5 ml/100 g/min (82% specificity and 83% sensitivity), which was greater in mice treated with MIL than those of control (51.7 versus 37.6 ml/100 g/min; P < 0.001). Conclusion MIL improves post-SAH acute hypoperfusion that can lead to the prevention of DCI and functional worsening, acting as a neurocardiac protective agent against EBI.
KW - Cardiac output
KW - Cerebral blood flow
KW - Delayed cerebral ischemia
KW - Early brain injury
KW - Milrinone
KW - Mouse model
KW - Subarachnoid hemorrhage
UR - http://www.scopus.com/inward/record.url?scp=85009865429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009865429&partnerID=8YFLogxK
U2 - 10.1016/j.neulet.2017.01.008
DO - 10.1016/j.neulet.2017.01.008
M3 - Article
C2 - 28069456
AN - SCOPUS:85009865429
SN - 0304-3940
VL - 640
SP - 70
EP - 75
JO - Neuroscience Letters
JF - Neuroscience Letters
ER -